Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Stern IR advising them

<< Previous

Bullboard Posts

Next >>

Comment by DIYGuyon Jul 28, 2017 11:44am

133 Views

Post# 26521734

RE:Stern IR advising them

Honestly, if you have been around this stock awhile you already know everything he will tell you. The company will release the cohort information in a press release when they have material news. They can only advise on the dose promotion when it occurs. Nothing else. In his defence I would be concerned if they told you more than the street knows. Also, the share consolidation was done to attract the funds who can only buy over $1. Paul Papi had a passionate story to tell but I wish I never heard it.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec